Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation

Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

(2013) Wendy L. Bennett et al.   ANNALS OF INTERNAL MEDICINE

Management of type 2 diabetes: NICE guidelines

(2013) L. Sibal et al.   CLINICAL MEDICINE

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

(2012) Odd Johansen et al.   Cardiovascular Diabetology

Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

(2012) Larry K. Golightly et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin

(2012) Ulrike Graefe-Mody et al.   CLINICAL PHARMACOKINETICS

Review of Linagliptin for the Treatment of Type 2 Diabetes Mellitus

(2012) Joshua J. Neumiller et al.   CLINICAL THERAPEUTICS

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

(2012) Stuart A. Ross et al.   CURRENT MEDICAL RESEARCH AND OPINION

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2012) T. Haak et al.   DIABETES OBESITY & METABOLISM

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

(2012) G. Schernthaner et al.   DIABETES OBESITY & METABOLISM

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

(2012) D. Singh-Franco et al.   DIABETES OBESITY & METABOLISM

Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis

(2012) S.-C. Liu et al.   DIABETES OBESITY & METABOLISM

Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus

(2012) S. K. Thondam et al.   DIABETIC MEDICINE

Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors

(2012) A. J. Scheen   DIABETOLOGIA

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Linagliptin

(2012) Emma D. Deeks   DRUGS

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment

(2012) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus

(2012) Elisa Guarino et al.   EXPERT OPINION ON PHARMACOTHERAPY

Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea

(2012) Ronnie Aronson   EXPERT OPINION ON PHARMACOTHERAPY

The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety

(2012) Sasiporn Wright et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers

(2012) Christian Friedrich et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension

(2012) R. Gomis et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes

(2012) Christopher Ll. Morgan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Choosing a blood-glucose-lowering agent after metformin

(2012) Michaela Diamant   LANCET

Gliptin versus a sulphonylurea as add-on to metformin

(2012) André J Scheen et al.   LANCET

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

(2012) Baptist Gallwitz et al.   LANCET

Metformin pathways

(2012) Li Gong et al.   Pharmacogenetics and Genomics

Use of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

(2012) Nasser Mikhail   POSTGRADUATE MEDICINE

Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications

(2012) Aleksi Tornio et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

(2012) Thomas Rauch et al.   Diabetes Therapy

Clinical Pharmacokinetics of Metformin

(2011) Garry G. Graham et al.   CLINICAL PHARMACOKINETICS

Cellular and molecular mechanisms of metformin: an overview

(2011) Benoit Viollet et al.   CLINICAL SCIENCE

A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects

(2011) Ulrike Graefe-Mody et al.   CLINICAL THERAPEUTICS

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review

(2011) Kathleen R. Richard et al.   CLINICAL THERAPEUTICS

Evaluating Treatment Algorithms for the Management of Patients With Type 2 Diabetes Mellitus: A Perspective on the Definition of Treatment Success

(2011) Richard B. Aguilar   CLINICAL THERAPEUTICS

Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients

(2011) Yoshiharu Horie et al.   CLINICAL THERAPEUTICS

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

(2011) Valerie Hutchins et al.   CURRENT MEDICAL RESEARCH AND OPINION

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

(2011) A.J. Scheen   DIABETES & METABOLISM

Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency

(2011) K. J. Lipska et al.   DIABETES CARE

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*

(2011) U. Graefe-Mody et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1

(2011) D. R. Owens et al.   DIABETIC MEDICINE

Linagliptin

(2011) Lesley J. Scott   DRUGS

Sitagliptin/Metformin Fixed-Dose Combination

(2011) Claudine M. Chwieduk   DRUGS

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

(2011) Roberta Baetta et al.   DRUGS

Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell

(2011) Andrew J. Mulherin et al.   ENDOCRINOLOGY

Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No

(2011) Sten Madsbad   European Journal of Internal Medicine

Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes

(2011) André J. Scheen   European Journal of Internal Medicine

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

(2011) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Metformin + saxagliptin for type 2 diabetes

(2011) André J Scheen   EXPERT OPINION ON PHARMACOTHERAPY

A review of gliptins in 2011

(2011) André J Scheen   EXPERT OPINION ON PHARMACOTHERAPY

Beyond Metformin: Initiating Combination Therapy in Patients with Type 2 Diabetes Mellitus

(2011) Jennifer D Goldman-Levine   PHARMACOTHERAPY

Review of the Safety and Efficacy of Linagliptin as Add-On Therapy to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study

(2011) Marc Rendell et al.   POSTGRADUATE MEDICINE

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

(2010) Silke Retlich et al.   CLINICAL PHARMACOKINETICS

Dipeptidylpeptitase-4 Inhibitors (Gliptins)

(2010) André J. Scheen   CLINICAL PHARMACOKINETICS

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

(2010) Akiko Sarashina et al.   CLINICAL THERAPEUTICS

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

(2010) C. Lamanna et al.   DIABETES OBESITY & METABOLISM

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

(2010) T. Forst et al.   DIABETIC MEDICINE

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

(2010) S. Blech et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

(2010) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of Target-Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP-4 Inhibition in Type 2 Diabetic Patients

(2010) Silke Retlich et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Addition of incretin therapy to metformin in type 2 diabetes

(2010) André J Scheen et al.   LANCET

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

(2009) E. U. Graefe-Mody et al.   CURRENT MEDICAL RESEARCH AND OPINION

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Fixed-dose single tablet antidiabetic combinations

(2009) C. J. Bailey et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

(2009) T. Heise et al.   DIABETES OBESITY & METABOLISM

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

(2009) E. Bosi et al.   DIABETES OBESITY & METABOLISM

Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes

(2009) J. Cuthbertson et al.   DIABETIC MEDICINE

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Hypoglycaemia in Type 2 diabetes

(2008) S. A. Amiel et al.   DIABETIC MEDICINE

Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

(2008) Bo Ahrén   EXPERT OPINION ON EMERGING DRUGS

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

(2008) S. Hüttner et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Polymorphism in human organic cation transporters and metformin action

(2008) Hiroshi Takane et al.   PHARMACOGENOMICS